Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
505.00    0.00 (0.00%)
Bid:
0.00
Ask:
540.00
Spread: 35.00 (6.931%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

6 Feb 2020 07:00

RNS Number : 1192C
Tate & Lyle PLC
06 February 2020
 

6 February 2020 - Tate & Lyle PLC

 

TRADING STATEMENT

 

Tate & Lyle issues the following trading statement for the three months ended 31 December 2019.

 

Group

 

The underlying performance of the Group was consistent with the first half and in line with our expectations. Our guidance for the year ending 31 March 2020 remains unchanged.

 

Food & Beverage Solutions

 

Adjusted operating profit performance in the quarter continued to be strong. Sales in all regions were ahead of the comparative period as we continued to drive good price and mix management, with volume overall broadly in line. While sales growth was slower in Asia Pacific and Latin America, we saw solid growth in North America and Europe, Middle East and Africa.

 

Sucralose

 

As expected, sales and adjusted operating profit were ahead of the comparative period reflecting good operational performance and the phasing of shipments from the first half into the quarter.

 

Primary Products

 

The division remains on track to deliver steady performance in the full year. In Sweeteners and Starches, profit was higher than the comparative period with strong performance in manufacturing and supply chain and good cost discipline more than offsetting lower sweetener demand from joint ventures and continued industrial starch softness. In Commodities, profit was ahead of the comparative period due to the earlier phasing of annual contracts.

 

The 2020 calendar year bulk sweetener pricing round is nearing completion with margins broadly in line with the prior year.

 

Guidance

 

Our guidance for the year ending 31 March 2020 remains unchanged and we continue to expect earnings per share growth in constant currency to be broadly flat to low-single digit.

 

END

 

 

 

A conference call will be held today at 08.00am GMT, hosted by Nick Hampton, Chief Executive and Imran Nawaz, Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call. Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666

Password: Tate & Lyle

 

A replay of this call will be available after the end of the live call for 14 days until 20 February 2020.

UK replay number: 0208 196 1998

Replay access PIN: 3146870

 

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP, Investor Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

 

Nick Hasell (FTI Consulting), Media Relations

Tel: +44 (0)20 3727 1234 or Mobile: +44 (0)7825 523 383

 

About Tate & Lyle:

Tate & Lyle is a global provider of solutions and ingredients for food, beverage and industrial markets.

Tate & Lyle operates through two global divisions, Food & Beverage Solutions and Primary Products, supported by the Innovation and Commercial Development and Global Operations teams. Food & Beverage Solutions is focused on growth by building leading positions globally in the categories of beverages, dairy, and soups, sauces and dressings. Primary Products is focused on delivering steady earnings and generating cash.

Food & Beverage Solutions consists of: Texturants, including speciality starches; Sweeteners, including low- and no-calorie sweeteners; and a Health and Wellness portfolio comprising mainly speciality fibres; and Stabilisers and Functional Systems, which are bespoke ingredient blends that ensure foods retain their structure.

Primary Products consists of high-volume sweeteners, industrial starches and fermentation products (primarily acidulants). It also sells co-products from the corn milling process as animal nutrition.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2019, Tate & Lyle sales totalled £2.8 billion. For more information, please visit http://www.tateandlyle.com or follow Tate & Lyle on Twitter or LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKKPBDOBKDQBK
Date   Source Headline
27th Mar 20262:00 pmRNSHolding(s) in Company
13th Mar 20264:00 pmRNSHolding(s) in Company
2nd Mar 20262:00 pmRNSHolding(s) in Company
26th Feb 20267:00 amRNSTrading Statement
23rd Feb 202610:00 amRNSHolding(s) in Company
17th Feb 202612:00 pmRNSHolding(s) in Company
21st Jan 20267:00 amRNSDirectorate change
15th Jan 20269:00 amRNSHolding(s) in Company
12th Jan 202610:00 amRNSHolding(s) in Company
7th Jan 20264:30 pmRNSDirector/PDMR Shareholding
7th Jan 20262:30 pmRNSBlock listing Interim Review
18th Dec 20252:00 pmRNSDirector/PDMR Shareholding
18th Dec 20252:00 pmRNSDirector/PDMR Shareholding
11th Dec 202512:18 pmRNSDirector/PDMR Shareholding
9th Dec 20259:00 amRNSHolding(s) in Company
27th Nov 202510:00 amRNSDirector/PDMR Shareholding
11th Nov 20254:30 pmRNSDirector/PDMR Shareholding
10th Nov 20252:40 pmRNSDirector Declaration
6th Nov 20257:00 amRNSHalf-year Financial Report
5th Nov 20252:15 pmRNSHolding(s) in Company
3rd Nov 20255:00 pmRNSHolding(s) in Company
29th Oct 20252:00 pmRNSHolding(s) in Company
23rd Oct 20254:15 pmRNSHolding(s) in Company
21st Oct 20253:30 pmRNSHolding(s) in Company
16th Oct 202512:00 pmRNSHolding(s) in Company
8th Oct 202512:00 pmRNSHolding(s) in Company
6th Oct 20254:30 pmRNSDirector/PDMR Shareholding
6th Oct 20254:00 pmRNSDirector/PDMR Shareholding
3rd Oct 20254:00 pmRNSDirector/PDMR Shareholding
3rd Oct 202510:00 amRNSDirector/PDMR Shareholding
1st Oct 20257:00 amRNSPre-close statement
2nd Sep 20258:00 amRNSTotal Voting Rights
11th Aug 20251:00 pmRNSDirector/PDMR Shareholding
5th Aug 20257:00 amRNSDirector/PDMR Shareholding
1st Aug 202511:00 amRNSTotal Voting Rights
24th Jul 20252:30 pmRNSResult of Annual General Meeting 2025
15th Jul 20251:00 pmRNSDirector/PDMR Shareholding
1st Jul 20253:30 pmRNSBlock listing Interim Review
1st Jul 20257:00 amRNSTate & Lyle Capital Markets Event
13th Jun 20253:00 pmRNSHolding(s) in Company
11th Jun 20254:30 pmRNSDirector/PDMR Shareholding
5th Jun 20252:30 pmRNSAnnual Financial Report and Notice of Meeting 2025
5th Jun 20252:00 pmRNSDirector/PDMR Shareholding
2nd Jun 202512:30 pmRNSTotal Voting Rights
28th May 202512:00 pmRNSDirector/PDMR Shareholding
27th May 202512:00 pmRNSDirector/PDMR Shareholding
23rd May 202510:00 amRNSDirector/PDMR Shareholding
22nd May 20257:00 amRNSFinal Results
14th May 20259:00 amRNSHolding(s) in Company
1st May 20253:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.